Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

In fact, the success of biosimilars in Europe has given the ... five years to achieve a 32 percent market share within the Filgrastim market. 3 In order to increase interest across products ...

IMS Health anticipates that biosimilars could save health systems ... and Sandoz's Zarzio (filgrastim-sndz), which are near copies of J&J's Remicade inflammatory diseases drug and Amgen's Neupogen ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

Although advanced biologics offer hope, their high prices add to the distress. Fortunately, now more affordable biosimilars- nearly identical to biologics – can substantially reduce costs. Therapeutic ...